Alpine Immune Sciences’ (ALPN) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a research note released on Wednesday, Marketbeat reports. They currently have a $26.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Alpine Immune Sciences’ FY2023 earnings at ($0.96) EPS, Q2 2024 earnings at ($0.20) EPS, […]

Leave a Reply

Your email address will not be published.

Previous post Brits warned of another tough winter ahead
Next post Clearwater Paper (NYSE:CLW) Upgraded to “Strong-Buy” by StockNews.com